Loading...
ANNX logo

Annexon, Inc.NasdaqGS:ANNX Stok Raporu

Piyasa Değeri US$879.8m
Hisse Fiyatı
US$5.21
US$13.13
60.3% değerinin altında içsel indirim
1Y159.2%
7D-8.4%
Portföy Değeri
​
Görünüm

Annexon, Inc.

NasdaqGS:ANNX Stok Raporu

Piyasa değeri: US$879.8m

Annexon (ANNX) Hisse Özeti

Klinik aşamada bir biyofarmasötik şirketi olan Annexon, Inc. iltihapla ilgili hastalıkların tedavisi için ilaçlar keşfetmekte ve geliştirmektedir. Daha fazla detay

Ödüller

Adil değer tahminimizden 95.2% daha düşük bir oranda işlem görüyor

Kazançların yılda 62.96% oranında artması öngörülüyor

Risk Analizi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Geliri 1 milyon ABD dolarından az ( $0 )

Son 3 ayda önemli miktarda içeriden satış gerçekleşti


ANNX Community Fair Values

Create Narrative

See what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Annexon, Inc. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Annexon
Tarihsel hisse senedi fiyatları
Güncel Hisse FiyatıUS$5.21
52 Haftanın En Yüksek SeviyesiUS$7.18
52 Haftanın En Düşük SeviyesiUS$1.80
Beta1.22
1 Aylık Değişim-17.95%
3 Aylık Değişim6.54%
1 Yıllık Değişim159.20%
3 Yıllık Değişim-11.69%
5 Yıllık Değişim-76.77%
Halka arzdan bu yana değişim-70.66%

Son Haberler & Güncellemeler

Analiz Makalesi • Apr 01

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, Annexon ( NASDAQ:ANNX...

Recent updates

Analiz Makalesi • Apr 01

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, Annexon ( NASDAQ:ANNX...
Seeking Alpha • Jan 24

Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases

Summary Annexon offers high-risk, high-reward potential with its C1q-targeted pipeline, led by tanruprubart for GBS and vonaprument for geographic atrophy. Tanruprubart’s Phase III results are promising, but there is U.S. regulatory uncertainty due to non-U.S. trial sites and dose-response questions. Vonaprument’s Phase III trial focuses on vision preservation, potentially differentiating ANNX in the competitive but large geographic atrophy market. I estimate fair value at $14.50/share, with 2026 as a pivotal year for clarity on the tanruprubart filing process, clinical vonaprument milestones, and possible commercial partnerships. Read the full article on Seeking Alpha
Analiz Makalesi • Oct 28

Is Annexon (NASDAQ:ANNX) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Jul 03

We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Mar 13

Annexon: Despite Major Catalysts, Stock Is Trading Almost At Cash

Summary Annexon’s lead candidate, ANX005, shows promise for treating Guillain-Barré Syndrome, achieving significant improvement in muscle strength and disability in phase 3 trials. Despite setbacks with ANX007 in Geographic Atrophy, the FDA approved a phase 3 trial focusing on vision preservation, with promising preliminary data. Financially, Annexon has a strong cash position, providing a runway of 5-8 quarters, but the stock trades almost at cash due to market skepticism. Risks include the ex-US trial locations for GBS and high short interest, but upcoming catalysts and a solid cash balance warrant close monitoring. Read the full article on Seeking Alpha
Analiz Makalesi • Mar 10

We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Jan 08

Annexon: Breakthrough In Guillain-Barré Faces Upcoming FDA Hurdles

Summary Annexon, Inc. trades at ~$5.05, down ~22% since my last article in April 2024, indicating ongoing investor skepticism. The Q3 2024 earnings release and 10-Q reveal mixed prospects, impacting investor confidence. Positive topline data from real-world evidence in Guillain-Barré syndrome presented in December 2024 offer a potential catalyst for future growth. Its decision to conduct its clinical trials in Asia creates a potential point of friction for an FDA approval. Read the full article on Seeking Alpha
Analiz Makalesi • Sep 27

We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 17

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Summary Annexon’s ANX005 shows promise for GBS. Phase 3 trial results indicate expedited recovery and durable benefits. ANNX targets the classical complement pathway, specifically the C1q protein, to address autoimmune, neurodegenerative, and ophthalmic conditions. The company’s pipeline includes ANX005, ANX007, and ANX1502. Due to its advanced development stage, ANX005 is the primary value driver. Financially, ANNX has a strong cash position and a 4.2-year runway, supporting further development towards a potential FDA approval for ANX005. While ANX005 is promising, its effectiveness is crucial compared to current GBS treatments, with upcoming comparability data being a key factor. Read the full article on Seeking Alpha
Seeking Alpha • Jun 04

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Summary Annexon, Inc. primary endpoint met with statistical significance in phase 3 Bangladesh and Philippines study, using ANX005 for the treatment of patients with Guillain-Barré syndrome. Results from RWS IGOS phase 3 study, using ANX005 for the treatment of patients with GBS, expected 1st half of 2025. If the primary endpoint of the RWS IGOS protocol study achieves a positive outcome, then a BLA filing is expected in the 1st half 2025. ANX007 is another C1q inhibitor in the pipeline, which is being developed to treat patients with geographic atrophy. Read the full article on Seeking Alpha
Seeking Alpha • Apr 03

Annexon: Unforced Error Sullies Prospects

Summary Annexon, Inc. is a clinical stage biotech company that is close to releasing topline data on its lead therapy, ANX005. ANX005 has the potential to become the first FDA approved therapy for Guillain-Barré syndrome (GBS). GBS is a rare disease that affects patients in different ways. Read the full article on Seeking Alpha
Analiz Makalesi • Nov 10

Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analiz Makalesi • Jul 25

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analiz Makalesi • Apr 11

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analiz Makalesi • Feb 14

Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Annexon, Inc...
Analiz Makalesi • Dec 28

We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Sep 16

Annexon started as a buy at Jefferies on market potential of candidates, data catalysts

Jefferies has initiated Annexion (NASDAQ:ANNX) with a buy rating saying that the company's candidates for conditions including Huntington's disease, Guillain-Barre Syndrome, and geographic atrophy are promising and have a large market potential. The firm has a $12 price target (~89% upside based on Thursday's close). Analyst Suji Jeong said that candidate ANX005 for Huntington's disease ("HD") has the potential to become the first disease-modifying therapy for the condition. It is currently in phase 2 for that indication. Jeong sets peak sales estimates of ANX005 in HD in the US and Europe at ~$400M. On ANX007 for geographic atrophy, currently in phase 2, Jeong wrote that it could address a market of 245K in the US. The analyst sees peak sales of ~$420M. Seeking Alpha's Quant Rating views Annexon (ANNX) as a buy with strong grades for momentum, growth, and revisions.
Seeking Alpha • Aug 21

Annexon: A First Take

Shares of clinical-stage biopharma Annexon are down by half since an early January 2022 data release revealed 5 of 28 patients dropped out of a Phase 2 Huntington’s disease study. Despite this setback, its lead candidate ANX005 appears to be efficacious and has been generally well-tolerated in studies encompassing 170 patients. With a market cap close to cash on hand after a private placement and multiple shots on goal, the recent insider buying warranted further investigation. A full investment analysis and recommendation follow in the paragraphs below. Failure is the condiment that gives success its flavor.”― Truman Capote Today, we take an in-depth look at a small biotech concern that had a recent setback but still has some 'shots on goal'. An analysis follows below. Seeking Alpha Company Overview: Annexon, Inc. (ANNX) is a Brisbane, California based clinical-stage biopharmaceutical concern focused on the development of therapies that treat complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. The company has three clinical assets, all of which target the initiating molecule of the classical complement pathway: C1q. Annexon was formed in 2011 and went public in 2020, raising net proceeds of $262.4 million at $17 per share. The stock currently trades around $5.50 a share, translating to a market cap of approximately $360 million including recently issued warrants. Complement System For those unfamiliar, the complement system is part of the body’s immune system and is responsible for aiding in the elimination of microbes and damaged cells through three pathways: the classical complement; the alternative complement; and the lectin. Comprised of proteins produced by the liver, overactivation of the classical complement pathway can cause severe immune and inflammatory disorders. C1q is a protein complex that is part of the classical complement pathway and is activated when it binds specific antigen-antibody complexes. When overactivated, it triggers a powerful inflammatory cascade through the instigation of downstream pathway components that can cause tissue-damaging diseases. Annexon’s precision medicine platform is designed to produce C1q targeting compounds to block the early inflammatory cascade while preserving the beneficial immune functions of the lectin and alternative complement pathways critical to the clearance of pathogens and damaged cells. Pipeline From this platform Annexon has developed three clinical assets. ANX005. The company’s lead candidate is ANX005, an intravenously administered monoclonal antibody designed to fully inhibit C1q throughout the body and across the blood brain barrier to combat autoimmune and neurodegenerative diseases. It is currently undergoing evaluation in four clinical trials, the most advanced of which is a Phase 2/3 clinical study for the treatment of Guillain-Barre Syndrome [GBS], a rare, acute, autoimmune disease damaging the peripheral nervous system of ~15,000 patients in North America and Europe with no approved therapies. The 180-patient, placebo-controlled trial is expected to readout in 2023 with primary endpoint change from baseline in GBS Disability Scale. In a completed Phase 1b study, ANX005 was well-tolerated and achieved C1q suppression in both the peripheral and central nervous systems. However, ANX005’s Phase 2 study for Huntington’s disease [HD] has been the subject of significant concern after an interim readout in early January 2022 revealed that despite half of the 28 patients in the trial (at that time) experiencing clinical improvement in disease progression, five discontinued treatment, which somewhat contradicted the company’s assertion that ANX005 had been generally well-tolerated. Shares of ANNX fell 34% to $7.26 in the subsequent trading session, initiating a crash into the mid-2s. A June 7th, 2022 data readout indicated that disease progression was stabilized in the overall HD population during both the six months of treatment and the three-month follow-up period. Nine of twelve patients with high complement levels demonstrated improvement at week 24 and maintained it through week 36. Furthermore, a biomarker for synapse loss remained generally consistent over the nine-month study period. Most importantly, no one else dropped from the study and the three patients determined to have developed treatment-related side effects had those events improve or resolve after discontinuation. All three cases were in patients with elevated antinuclear antibody (ANA) titers at baseline. No patient with normal ANA titers experienced a severe adverse event. HD is a hereditary neurodegenerative disorder characterized by abnormal involuntary movements, progressive dementia, depression, and psychosis. In HD, C1q inappropriately tags synapses in the brain, sparking their destruction, inducing neurodegeneration. Onset of symptoms typically occurs between 30 to 50 years of age with death from cardio-respiratory complications approximately 10 to 20 years thereafter. Although there is medication to treat some of HD’s symptoms, there are no remedies that address its root cause for the ~30,000 Americans (80,000 globally) afflicted. The early June readout somewhat validated Annexon’s precision medicine approach and triggered a 25% one-day rally to $4.06 a share. This news was later used to execute a private placement – more on that below. ANX005 is also being studied in a Phase 2 trial for the treatment of warm autoimmune hemolytic anemia (AIHA), a malady characterized by the presence of auto-antibodies that bind to red blood cells. The temperature at which the binding occurs determines the warm or cold designation. Warm AIHA affects ~30,000 patients globally, with ~11% progressing to death. Data from the trial are anticipated in 2H22. Finally, ANX005 is undergoing Phase 2 assessment in the treatment of amyotrophic lateral sclerosis (ALS), the infamous devastating neurodegenerative disease that afflicts ~30,000 patients worldwide. A readout from the study is expected in 2023. The therapy has received Orphan Drug status from the FDA for GBS and HD as well as Fast Track designation for GBS. ANX007. Annexon’s other asset in a Phase 2 trial is ANX007, a formulation of an antigen-binding fragment [FAB] that is designed to inhibit C1q locally in the eye (initially) for patients with geographic atrophy [GA]. Also known as atrophic age-related macular degeneration, GA affects more than 5 million worldwide and has no approved treatment options. Topline data for the intravitreally administered therapy is expected in 1H23. ANX009. The company is also investigating ANX009, a subcutaneous formulation of a Fab designed to inhibit C1q only in the vascular space for the treatment of lupus nephritis. An ongoing Phase 1b trial is expected to produce initial data sometime in 2H22. Balance Sheet & Analyst Commentary: Management elected to leverage the somewhat positive news from the HD trial into a very dilutive capital raise, executing a private placement that raised gross proceeds of $130 million, consisting of common stock and pre-funded warrants representing 33.7 million shares at a price of ~$3.87, essentially doubling the total shares outstanding. Additionally, 8.4 million three-year common warrants with an exercise price of ~$5.81 were issued. This transaction, which closed on July 11, 2022, increased Annexon’s cash position to ~$300 million with no debt, providing it an operating runway into 2H25.
Seeking Alpha • Aug 08

Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02

Annexon Biosciences press release (NASDAQ:ANNX): Q2 GAAP EPS of -$0.96 misses by $0.02. Cash and cash equivalents and short-term investments were $177.6 million as of June 30, 2022, which does not include the approximately $130 million in gross proceeds from the company’s recently completed private placement.
Seeking Alpha • Jul 08

Annexon to raise $130M in stock and warrant offering

Annexon (NASDAQ:ANNX) entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of ~$130M. The company is selling 9.01M shares, pre-funded warrants to purchase up to 24.7M shares and accompanying warrants to purchase up to 8.4M shares at a combined price of $3.87/share of stock and accompanying warrant and $3.87 for pre-funded warrant and accompanying common warrant. The accompanying common warrants will have an exercise price of $5.8/share and will be immediately exercisable and expire on June 30, 2025. Offer is expected to close on July 11, 2022. Shares trading 3.3% higher premarket.
Analiz Makalesi • Apr 16

We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analiz Makalesi • Jan 01

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Sep 08

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Hissedar Getirileri

ANNXUS BiotechsUS Pazar
7D-8.4%-1.6%-0.9%
1Y159.2%34.4%24.4%

Getiri vs. Endüstri: ANNX geçen yıl % 34.4 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: ANNX geçen yıl % 24.4 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is ANNX's price volatile compared to industry and market?
ANNX volatility
ANNX Average Weekly Movement9.2%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.1%

İstikrarlı Hisse Senedi Fiyatı: ANNX son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: ANNX 'nin haftalık oynaklığı ( 9% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
201193Doug Lovewww.annexonbio.com

Klinik aşamada bir biyofarmasötik şirketi olan Annexon, Inc. iltihapla ilgili hastalıkların tedavisi için ilaçlar keşfetmekte ve geliştirmektedir. Şirket, guillain-barré sendromlu hastaların tedavisi için Faz 3 klinik çalışmasında olan; Huntington hastalığının tedavisi için Faz II klinik çalışmasını tamamlayan ve amiyotrofik lateral skleroz tedavisi için Faz 2a klinik çalışmasında olan araştırma amaçlı tam uzunlukta bir monoklonal antikor olan Tanruprubart'ı sunmaktadır. Ayrıca, coğrafi atrofi hastalarının tedavisi için Faz 3 programında olan bir antijen bağlayıcı fragman (Fab) olan ANX007'yi ve otoimmün endikasyonlar için Faz 1 klinik çalışmalarında olan yeni bir oral küçük molekül inhibitörü olan ANX1502'yi geliştirmektedir.

Annexon, Inc. Temel Bilgiler Özeti

Annexon'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ANNX temel i̇stati̇sti̇kler
Piyasa değeriUS$879.83m
Kazançlar(TTM)-US$198.33m
Gelir(TTM)n/a
0.0x
P/S Oranı
-4.3x
F/K Oranı

ANNX aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ANNX gelir tablosu (TTM)
GelirUS$0
Gelir MaliyetiUS$0
Brüt KârUS$0
Diğer GiderlerUS$198.33m
Kazançlar-US$198.33m

Son Raporlanan Kazançlar

Mar 31, 2026

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)-1.21
Brüt Marj0.00%
Net Kâr Marjı0.00%
Borç/Özkaynak Oranı0%

ANNX uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/15 11:06
Gün Sonu Hisse Fiyatı2026/05/15 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Annexon, Inc. 13 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Tazeen AhmadBofA Global Research
Thomas ShraderBTIG
Pete StavropoulosCantor Fitzgerald & Co.